Critical Care Management of the ACHD Patient with Heart Failure

  • Leigh Christopher ReardonEmail author
  • Eugene Depasquale
  • Weiyi Tan
Part of the Congenital Heart Disease in Adolescents and Adults book series (CHDAA)


As more patients with congenital heart disease live into adulthood, the burden of late complications of their condition, especially heart failure, will continue to increase. Clinicians currently rely on well-established guidelines based on robust clinical trials to provide evidence-based treatment for adults without congenital heart disease who are hospitalized with heart failure. The management of adult patients with congenital heart disease in heart failure, however, is less well defined, and the correct course of action may not always be apparent. The adult population of patients with congenital heart disease is a very heterogeneous group that comprises many different physiologic states and a variety of surgical repairs. Patients with systemic left ventricles will manifest with heart failure symptoms differently than patients with a single ventricle or those with a systemic right ventricle. This chapter will discuss the presentation of heart failure in varying types of adult congenital cardiac conditions and the nuanced and individualized treatments required to manage each patient successfully through an exacerbation of heart failure requiring hospitalization.


Adult congenital heart disease (ACHD) Heart failure ICU care of ACHD Systemic left ventricle Systemic right ventricle Single ventricle Cardiomyopathy Right heart failure Left heart failure 


  1. 1.
    Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749–56.PubMedCrossRefGoogle Scholar
  2. 2.
    Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007;115(2):163–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Bhatt AB, Foster E, Kuehl K, Alpert J, Brabeck S, Crumb S, et al. Congenital heart disease in the older adult: a scientific statement from the American Heart Association. Circulation. 2015;131:1884–931. Scholar
  4. 4.
    Opotowsky AR, Siddiqi OK, Webb GD. Trends in hospitalizations for adults with congenital heart disease in the U.S. J Am Coll Cardiol. 2009;54(5):460–7. Scholar
  5. 5.
    Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol. 2008;52(23):1890–947. Scholar
  6. 6.
    Baumgartner H, Bonhoeffer P, De Groot NMS, De Haan F, Deanfield JE, Galie N, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31(23):2915–57.PubMedGoogle Scholar
  7. 7.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol. 2009;53(15):e1–90. Scholar
  8. 8.
    Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016;133:770–801.PubMedCrossRefGoogle Scholar
  9. 9.
    Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112(6):828–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Wald RM, Marie Valente A, Marelli A. Heart failure in adult congenital heart disease: emerging concepts with a focus on tetralogy of Fallot. Trends Cardiovasc Med. 2015;25(5):422–32. Scholar
  11. 11.
    Moussa NB, Karsenty C, Pontnau F, Malekzadeh-Milani S, Boudjemline Y, Legendre A, et al. Characteristics and outcomes of heart failure-related hospitalization in adults with congenital heart disease. Arch Cardiovasc Dis. 2017;110:1–9. Scholar
  12. 12.
    Alshawabkeh LI, Opotowsky AR. Burden of heart failure in adults with congenital heart disease. Curr Heart Fail Rep. 2016;13(5):247–54. Scholar
  13. 13.
    Piran S, Veldtman G, Siu S, Webb GD, Liu PP. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation. 2002;105(10):1189–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Khairy P, Ionescu-Ittu R, MacKie AS, Abrahamowicz M, Pilote L, Marelli AJ. Changing mortality in congenital heart disease. J Am Coll Cardiol. 2010;56(14):1149–57. Scholar
  15. 15.
    Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late causes of death after pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol. 2016;68(5):487–98.PubMedCrossRefGoogle Scholar
  16. 16.
    Dinardo JA. Heart failure associated with adult congenital heart disease. Semin Cardiothorac Vasc Anesth. 2013;17(1):44–54. Scholar
  17. 17.
    Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002;106(1):92–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Giannakoulas G, Dimopoulos K, Bolger AP, Tay EL, Inuzuka R, Bedard E, et al. Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol. 2010;105(6):869–73. Scholar
  19. 19.
    Reardon LC, Williams RJ, Houser LS, Miner PD, Child JS, Aboulhosn JA. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the eisenmenger syndrome. Am J Cardiol. 2012;110(10):1523–6. Scholar
  20. 20.
    Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population: Impact on outcomes. J Am Coll Cardiol. 2011;58(5):538–46. Scholar
  21. 21.
    Fahed AC, Roberts AE, Mital S, Lakdawala NK. Heart failure in congenital heart disease. A confluence of acquired and congenital. Heart Fail Clin. 2014;10(1):219–27.PubMedCrossRefGoogle Scholar
  22. 22.
    Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112(4):707–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Mcmurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail. 2012;14(8):803–69.PubMedCrossRefGoogle Scholar
  24. 24.
    Budts W, Roos-Hesselink J, Rädle-Hurst T, Eicken A, McDonagh TA, Lambrinou E, et al. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2016;37(18):1419–27.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Ryan TD, Jefferies JL, Wilmot I. Managing heart failure in adults with congenital heart disease. Curr Treat Options Cardiovasc Med. 2015;17(2):376.PubMedCrossRefGoogle Scholar
  26. 26.
    Babu-Narayan SV, Uebing A, Davlouros PA, Kemp M, Davidson S, Dimopoulos K, et al. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention of the deleterious effects of Pulmonary Regurgitation in Adults with repaired TEtralogy of Fallot). Int J Cardiol. 2012;154(3):299–305. Scholar
  27. 27.
    Dimopoulos K, Diller GP, Koltsida E, Pijuan-Domenech A, Papadopoulou SA, Babu-Narayan SV, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2008;117(18):2320–8. Scholar
  28. 28.
    Allan CK. Intensive care of the adult patient with congenital heart disease. Prog Cardiovasc Dis. 2011;53(4):274–80. Scholar
  29. 29.
    Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29(13):1681–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Roy N. Critical care management of the adult patient with congenital heart disease: focus on postoperative management and outcomes. Curr Treat Options Cardiovasc Med. 2015;17(2):1–11.CrossRefGoogle Scholar
  31. 31.
    Krieger EV, Valente AM. Heart failure treatment in adults with congenital heart disease: where do we stand in 2014? Heart. 2014;100(17):1329–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Stefanescu A, Macklin EA, Lin E, Dudzinski DM, Johnson J, Kennedy KF, et al. Usefulness of the Seattle Heart Failure Model to identify adults with congenital heart disease at high risk of poor outcome. Am J Cardiol. 2014;113(5):865–70. Scholar
  33. 33.
    Pignatelli RH, McMahon CJ, Chung T, Vick GW 3rd. Role of echocardiography versus MRI for the diagnosis of congenital heart disease. Curr Opin Cardiol. 2003;18(5):357–65. Scholar
  34. 34.
    Burchill LJ, Huang J, Tretter JT, Khan AM, Crean AM, Veldtman GR, et al. Noninvasive imaging in adult congenital heart disease. Circ Res. 2017;120(6):995–1014. Scholar
  35. 35.
    Warnes CA, Bhatt AB, Daniels CJ, Gillam LD, Stout KK. COCATS 4 task force 14: training in the care of adult patients with congenital heart disease. J Am Coll Cardiol. 2015;65(17):1887–98. Scholar
  36. 36.
    Diller GP, Kempny A, Liodakis E, Alonso-Gonzalez R, Inuzuka R, Uebing A, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of Fallot. Circulation. 2012;125(20):2440–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Kalogeropoulos AP, Deka A, Border W, Pernetz MA, Georgiopoulou VV, Kiani J, et al. Right ventricular function with standard and speckle-tracking echocardiography and clinical events in adults with D-transposition of the great arteries post atrial switch. J Am Soc Echocardiogr. 2012;25(3):304–12. Scholar
  38. 38.
    Cioccari L, Baur H-R, Berger D, Wiegand J, Takala J, Merz TM. Hemodynamic assessment of critically ill patients using a miniaturized transesophageal echocardiography probe. Crit Care. 2013;17(3):R121. Scholar
  39. 39.
    Hammoudi N, Hékimian G, Laveau F, Achkar M, Isnard R, Combes A. Three-dimensional transoesophageal echocardiography for cardiac output in critically ill patients: a pilot study of ultrasound versus the thermodilution method. Arch Cardiovasc Dis. 2017;110(1):7–13. Scholar
  40. 40.
    Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. Eur Heart J. 2010;31(7):794–805.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Inuzuka R, Diller GP, Borgia F, Benson L, Tay ELW, Alonso-Gonzalez R, et al. Comprehensive use of cardiopulmonary exercise testing identifies adults with congenital heart disease at increased mortality risk in the medium term. Circulation. 2012;125(2):250–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Binanay C, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625–33.PubMedCrossRefGoogle Scholar
  43. 43.
    Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–66.PubMedCrossRefGoogle Scholar
  44. 44.
    Bradley EA, Berman D, Daniels CJ. First implantable hemodynamic monitoring device placement in single ventricle fontan anatomy. Catheter Cardiovasc Interv. 2016;88(2):248–52. Scholar
  45. 45.
    Perry J, Lanzberg M, Franklin W, Webb G, Chang AC. Cardiac intensive care of the adult with congenital heart disease: basic principles in the management of common problems. World J Pediatr Congenit Heart Surg. 2011;2(3):430–44.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. 2005;112(16):2411–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Doughan ARK, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol. 2007;99(5):704–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Van Der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, et al. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127(3):322–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Bouallal R, Godart F, Francart C, Richard A, Foucher-Hossein C, Lions C. Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young. 2010;20(6):615–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Dos L, Pujadas S, Estruch M, Mas A, Ferreira-González I, Pijuan A, et al. Eplerenone in systemic right ventricle: double blind randomized clinical trial. the evedes study. Int J Cardiol. 2013;168(6):5167–73. Scholar
  51. 51.
    Norozi K, Bahlmann J, Raab B, Alpers V, Arnhold JO, Kuehne T, et al. A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. Cardiol Young. 2007;17(4):372–9. Scholar
  52. 52.
    Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.PubMedCrossRefGoogle Scholar
  53. 53.
    Shabanian R, Shahbaznejad L, Razaghian A, Kiani A, Rahimzadeh M, Seifirad S, et al. Sildenafil and ventriculo-arterial coupling in fontan-palliated patients: a noninvasive echocardiographic assessment. Pediatr Cardiol. 2013;34(1):129–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Ringel RE, Peddy SB. Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol. 2003;91(8):1031–2.PubMedCrossRefGoogle Scholar
  55. 55.
    Mahle WT, Wang A, Quyyumi AA, McConnell ME, Book WM. Impact of spironolactone on endothelial function in patients with single ventricle heart. Congenit Heart Dis. 2009;4(1):12–6.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation. 1997;96(5):1507–12.PubMedCrossRefGoogle Scholar
  57. 57.
    Ishibashi N, Park I-S, Waragai T, Yoshikawa T, Murakami Y, Mori K, et al. Effect of carvedilol on heart failure in patients with a functionally univentricular heart. Circ J. 2011;75(6):1394–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.PubMedCrossRefGoogle Scholar
  59. 59.
    McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. Scholar
  60. 60.
    Tay ELW, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151(3):307–12. Scholar
  61. 61.
    Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010;121(1):20–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Diller GP, Alonso-Gonzalez R, Dimopoulos K, Alvarez-Barredo M, Koo C, Kempny A, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. 2013;167(3):840–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Méndez AB, Colchero T, Garcia-Picart J, Vila M, Subirana MT, Sionis A. Unusual case of new-onset heart failure due to cor triatriatum sinister. Eur J Heart Fail. 2013;15(2):237–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395–406. Scholar
  65. 65.
    Hammerstingl C, Schueler R, Malasa M, Werner N, Nickenig G. Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system. Eur Heart J. 2016;37(10):849–53. Scholar
  66. 66.
    Taramasso M, Pozzoli A, Guidotti A, Nietlispach F, Inderbitzin DT, Benussi S, et al. Percutaneous tricuspid valve therapies: the new frontier. Eur Heart J. 2017;38:639–47. Scholar
  67. 67.
    Franzen O, von Samson P, Dodge-Khatami A, Geffert G, Baldus S. Percutaneous edge-to-edge repair of tricuspid regurgitation in congenitally corrected transposition of the great arteries. Congenit Heart Dis. 2011;6(1):57–9. Scholar
  68. 68.
    Valente AM, Gauvreau K, Assenza GE, Babu-Narayan SV, Schreier J, Gatzoulis MA, et al. Contemporary predictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100(3):247–53. Scholar
  69. 69.
    Khairy P, van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Can J Cardiol. 2014;30(10):e1–63. Scholar
  70. 70.
    Cecchin F, Frangini PA, Brown DW, Fynn-Thompson F, Alexander ME, Triedman JK, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. J Cardiovasc Electrophysiol. 2009;20(1):58–65.PubMedCrossRefGoogle Scholar
  71. 71.
    Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol. 2005;46(12):2277–83. Scholar
  72. 72.
    Janousek J, Gebauer RA, Abdul-Khaliq H, Turner M, Kornyei L, Grollmuss O, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart. 2009;95(14):1165–71. Scholar
  73. 73.
    Lindsay I, Moore JP. Cardiac arrhythmias in adults with congenital heart disease: scope, specific problems, and management. Curr Treat Options Cardiovasc Med. 2015;17(12):56.PubMedCrossRefGoogle Scholar
  74. 74.
    Gelow JM, Song HK, Weiss JB, Mudd JO, Broberg CS. Organ allocation in adults with congenital heart disease listed for heart transplant: Impact of ventricular assist devices. J Heart Lung Transplant. 2013;32(11):1059–64. Scholar
  75. 75.
    Shah NR, Lam WW, Rodriguez FH, Ermis PR, Simpson L, Frazier OH, et al. Clinical outcomes after ventricular assist device implantation in adults with complex congenital heart disease. J Heart Lung Transplant. 2013;32(6):1–6. Scholar
  76. 76.
    Burchill LJ. Heart transplantation in adult congenital heart disease. Heart. 2016;102(23):1871–7. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Leigh Christopher Reardon
    • 1
    • 2
    Email author
  • Eugene Depasquale
    • 3
  • Weiyi Tan
    • 2
  1. 1.Department of Medicine and Pediatric CardiologyRonald Reagan UCLA Medical CenterLos AngelesUSA
  2. 2.Department of Medicine and CardiologyRonald Reagan UCLA Medical CenterLos AngelesUSA
  3. 3.Division of Cardiology, Department of MedicineAhmanson/UCLA Cardiomyopathy Center, David Geffen School of MedicineLos AngelesUSA

Personalised recommendations